AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Transient receptor potential cation channel subfamily V member 5

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9NQA5

UPID:

TRPV5_HUMAN

Alternative names:

Calcium transport protein 2; Epithelial calcium channel 1; Osm-9-like TRP channel 3

Alternative UPACC:

Q9NQA5; A4D2H7; E9PBZ6; Q8N4C1; Q8NDW5; Q8NDX7; Q8NDX8; Q96PM6

Background:

Transient receptor potential cation channel subfamily V member 5 (TRPV5), also known as Calcium transport protein 2, plays a pivotal role in calcium homeostasis by facilitating calcium reabsorption in kidney and intestine. It operates as a constitutively active calcium-selective channel, which is crucial for maintaining normal calcium levels in the body. The channel's activity is modulated by internal calcium levels, exhibiting inward rectification and a Ca(2+)-dependent feedback mechanism for regulation.

Therapeutic significance:

Understanding the role of Transient receptor potential cation channel subfamily V member 5 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.